《股市简讯》中国康哲药业涨3.8%，引进的卒中药物上市申请获国家药监局受理

路透中文

2025/12/12

《股市简讯》中国<a href="https://laohu8.com/S/00867">康哲药业</a>涨3.8%，引进的卒中药物上市申请获国家药监局受理

* 中国康哲药业0867.HK周五早盘涨幅扩大至3.8%。

* 该公司此前公告称，注射用洛贝米柳新药上市许可申请获得中国国家药品监督管理局受理，产品为一种拟用于急性缺血性卒中的脑细胞保护剂。该药物由南京宁丹新药研发，康哲药业在2023年获得产品在中国大陆、香港、澳门的独家推广权。

* 康哲药业今年迄今劲涨71.7%，同期恒生指数.HSI上扬28.3%。

* 恒生综合行业指数 - 医疗保健业.HSCIH盘中一度跌0.4%。（完）

更多股市简讯请点选CN-CMN-HOT

(发稿徐凯文；审校张喜良)

((kaiwen.xu@thomsonreuters.com))

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2590250915"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2590250915\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2590250915?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-12-12 10:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590250915","market":"hk","top_or_hot":-1,"title":"《股市简讯》中国康哲药业涨3.8%，引进的卒中药物上市申请获国家药监局受理","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>《股市简讯》中国<a href=\"https://laohu8.com/S/00867\">康哲药业</a>涨3.8%，引进的卒中药物上市申请获国家药监局受理</title></head><body><p>* 中国康哲药业<span>0867.HK</span>周五早盘涨幅扩大至3.8%。</p><p>* 该公司此前公告称，注射用洛贝米柳新药上市许可申请获得中国国家药品监督管理局受理，产品为一种拟用于急性缺血性卒中的脑细胞保护剂。该药物由南京宁丹新药研发，康哲药业在2023年获得产品在中国大陆、香港、澳门的独家推广权。</p><p>* 康哲药业今年迄今劲涨71.7%，同期恒生指数<span>.HSI</span>上扬28.3%。</p><p>* 恒生综合行业指数 - 医疗保健业<span>.HSCIH</span>盘中一度跌0.4%。（完）</p><p>更多股市简讯请点选<span>CN-CMN-HOT</span></p><p> (发稿 徐凯文；审校 张喜良)</p><p> ((kaiwen.xu@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>《股市简讯》中国康哲药业涨3.8%，引进的卒中药物上市申请获国家药监局受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n《股市简讯》中国康哲药业涨3.8%，引进的卒中药物上市申请获国家药监局受理\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2025-12-12 10:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>《股市简讯》中国<a href=\"https://laohu8.com/S/00867\">康哲药业</a>涨3.8%，引进的卒中药物上市申请获国家药监局受理</title></head><body><p>* 中国康哲药业<span>0867.HK</span>周五早盘涨幅扩大至3.8%。</p><p>* 该公司此前公告称，注射用洛贝米柳新药上市许可申请获得中国国家药品监督管理局受理，产品为一种拟用于急性缺血性卒中的脑细胞保护剂。该药物由南京宁丹新药研发，康哲药业在2023年获得产品在中国大陆、香港、澳门的独家推广权。</p><p>* 康哲药业今年迄今劲涨71.7%，同期恒生指数<span>.HSI</span>上扬28.3%。</p><p>* 恒生综合行业指数 - 医疗保健业<span>.HSCIH</span>盘中一度跌0.4%。（完）</p><p>更多股市简讯请点选<span>CN-CMN-HOT</span></p><p> (发稿 徐凯文；审校 张喜良)</p><p> ((kaiwen.xu@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BMCWC346.EUR","symbol_name":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (EUR) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nL4S3XI03Q:1","article_id":"2590250915","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590250915","pubTimestamp":1765504877,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"《股市简讯》中国康哲药业涨3.8%，引进的卒中药物上市申请获国家药监局受理* 中国康哲药业0867.HK周五早盘涨幅扩大至3.8%。* 该公司此前公告称，注射用洛贝米柳新药上市许可申请获得中国国家药品监督管理局受理，产品为一种拟用于急性缺血性卒中的脑细胞保护剂。该药物由南京宁丹新药研发，康哲药业在2023年获得产品在中国大陆、香港、澳门的独家推广权。* 康哲药业今年迄今劲涨71.7%，同期恒生指数.HSI上扬28.3%。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00BMCWC346.EUR":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (EUR) ACC","BK1593":"医美概念股","BK1191":"制药","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","IE00BVYPNQ40.USD":"GUINNESS ASIAN EQUITY INCOME \"C\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","IE00BYV24P56.USD":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (USD) ACC","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","SG9999015978.USD":"利安颠覆性创新基金A","IE00BVYPNP33.GBP":"GUINNESS ASIAN EQUITY INCOME \"C\" (GBP) ACC","00867":"康哲药业","IE00BGHQDM52.EUR":"GUINNESS ASIAN EQUITY INCOME \"C\" (EUR) ACC"},"translate_title":"\"Stock Market Newsletter\" China CMS Pharmaceutical rose 3.8%, and the application for the marketing of the introduced stroke drug was accepted by the State Food and Drug Administration","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00867":0.9},"content_text":"《股市简讯》中国康哲药业涨3.8%，引进的卒中药物上市申请获国家药监局受理* 中国康哲药业0867.HK周五早盘涨幅扩大至3.8%。* 该公司此前公告称，注射用洛贝米柳新药上市许可申请获得中国国家药品监督管理局受理，产品为一种拟用于急性缺血性卒中的脑细胞保护剂。该药物由南京宁丹新药研发，康哲药业在2023年获得产品在中国大陆、香港、澳门的独家推广权。* 康哲药业今年迄今劲涨71.7%，同期恒生指数.HSI上扬28.3%。* 恒生综合行业指数 - 医疗保健业.HSCIH盘中一度跌0.4%。（完）更多股市简讯请点选CN-CMN-HOT (发稿 徐凯文；审校 张喜良) ((kaiwen.xu@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}